• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    32401426.pdf
    Size:
    1.252Mb
    Format:
    PDF
    Description:
    FROM CORE
    Download
    Authors
    Roseweir, A. K.
    Park, J. H.
    Hoorn, S. T.
    Powell, A. G.
    Aherne, S.
    Roxburgh, C. S.
    McMillan, D. C.
    Horgan, P. G.
    Ryan, E.
    Sheahan, K.
    Vermeulen, L.
    Paul, J.
    Harkin, A.
    Graham, J.
    Sansom, O.
    Church, D. N.
    Tomlinson, I.
    Saunders, Mark P
    Iveson, T. J.
    Edwards, J.
    Show allShow less
    Affiliation
    School of Medicine, University of Glasgow, Glasgow, UK.
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Histological 'phenotypic subtypes' that classify patients into four groups (immune, canonical, latent and stromal) have previously been demonstrated to stratify survival in a stage I-III colorectal cancer (CRC) pilot cohort. However, clinical utility has not yet been validated. Therefore, this study assessed prognostic value of these subtypes in additional patient cohorts along with associations with risk of recurrence and response to chemotherapy. Two independent stage I-III CRC patient cohorts (internal and external cohort) were utilised to investigate phenotypic subtypes. The primary endpoint was disease-free survival (DFS) and the secondary endpoint was recurrence risk (RR). Stage II-III patients, from the SCOT adjuvant chemotherapy trial, were utilised to further validate prognostic value and for exploratory analysis assessing associations with adjuvant chemotherapy. In an 893-patient internal cohort, phenotypic subtype independently associated with DFS (p = 0.025) and this was attenuated in stage III patients (p = 0.020). Phenotypic subtype also independently associated with RR (p < 0.001) in these patients. In a 146-patient external cohort, phenotypic subtype independently stratified patients by DFS (p = 0.028), validating their prognostic value. In 1343 SCOT trial patients, the effect of treatment type significantly depended on phenotypic subtype (pinteraction = 0.011). Phenotypic subtype independently associated with DFS in stage III patients receiving FOLFOX (p = 0.028). Furthermore, the immune subtype significantly associated with better response to FOLFOX compared to CAPOX adjuvant chemotherapy in stage III patients (p = 0.013). In conclusion, histological phenotypic subtypes are an effective prognostic classification in patients with stage III CRC that associates with risk of recurrence and response to FOLFOX adjuvant chemotherapy.
    Citation
    A. K. Roseweir, J. H. Park, S. T. Hoorn et al. Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. J Pathol Clin Res. 2020.
    Journal
    Journal of Pathology Clinical Research
    URI
    http://hdl.handle.net/10541/623018
    DOI
    10.1002/cjp2.171
    PubMed ID
    32401426
    Additional Links
    https://dx.doi.org/10.1002/cjp2.171
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1002/cjp2.171
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    • Authors: Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A
    • Issue date: 2020 Apr 1
    • Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
    • Authors: Kwon Y, Park M, Jang M, Yun S, Kim WK, Kim S, Paik S, Lee HJ, Hong S, Kim TI, Min B, Kim H
    • Issue date: 2017 Jun 13
    • Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    • Authors: Tsuruta A, Yamashita K, Tanioka H, Tsuji A, Inukai M, Yamakawa T, Yamatsuji T, Yoshimitsu M, Toyota K, Yamano T, Nagasaka T, Okajima M
    • Issue date: 2016
    • The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
    • Authors: Alexander PG, Roseweir AK, Pennel KAF, van Wyk HC, Powell AGMT, McMillan DC, Horgan PG, Kelly C, Hay J, Sansom O, Harkin A, Roxburgh CSD, Graham J, Church DN, Tomlinson I, Saunders M, Iveson TJ, Edwards J, Park JH
    • Issue date: 2021 Feb
    • Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    • Authors: Gao S, Tibiche C, Zou J, Zaman N, Trifiro M, O'Connor-McCourt M, Wang E
    • Issue date: 2016 Jan
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.